Message From the Editor-in-Chief
Message From the Editor-in-Chief
2017 Volume 81 Issue 8 Pages 1063-1064
Details
2017 Volume 81 Issue 8 Pages 1063-1064
Dear Colleagues,
On behalf of the Circulation Journal, I would like to report the official 2016 impact factor and the Circulation Journal papers (2014–2015) most frequently quoted in 2016, that substantially contributed to the 2016 impact factor of the Journal.
1. The Official 2016 Impact FactorI would like to report that Circulation Journal has earned an official 2016 Impact Factor (IF) of 3.544. The official ranking also places Circulation Journal 44th among the 126 journals in the Cardiac & Cardiovascular Systems category in 2016 JCR Science Edition (31st among the 124 journals in 2015). We analyzed that the decrease in the IF this year was due to the reduction of the number of self citation. I would like to ask readers to cite Circulation Journal papers in your future submission of manuscripts to any journals.
2. The Most Frequently Quoted CJ Papers (2014–2015) in 2016The following papers, published in 2014–2015, were among the top 31 most frequently quoted papers in 2016, thereby substantially contributing to the 2016 Impact Factor of the Journal (number in the parenthesis denoted the number of quotation in 2014–2015).
1. (40) JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997–2021.
2. (22) Scantlebury DC, Prasad A. Diagnosis of Takotsubo cardiomyopathy: Mayo Clinic criteria. Circ J 2014; 78: 2129–2139.
3. (19) JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): Digest version. Circ J 2014; 78: 2779–2801.
4. (16) De Paoli F, Staels B, Chinetti-Gbaguidi G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J 2014; 78: 1775–1781.
(16) Sharkey SW, Maron BJ. Epidemiology and clinical profile of Takotsubo cardiomyopathy. Circ J 2014; 78: 2119–2128.
6. (15) Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 2014; 78: 2807–2818.
(15) Mizusawa Y, Horie M, Wilde AAM. Genetic and clinical advances in congenital long QT syndrome. Circ J 2014; 78: 2827–2833.
(15) Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al; on behalf of the SYMPLICITY HTN-Japan Investigators. SYMPLICITY HTN-Japan: First randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J 2015; 79: 1222–1229.
(15) Momomura S, Seino Y, Kihara Y, Adachi H, Yasumura Y, Yokoyama H, et al; for the SAVIOR-C investigators. Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J 2015; 79: 981–990.
(15) Ishihara M, Fujino M, Ogawa H, Yasuda S, Noguchi T, Nakao K, et al; on behalf of the J-MINUET investigators. Clinical presentation, management and outcome of Japanese patients with acute myocardial infarction in the troponin era: Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET). Circ J 2015; 79: 1255–1262.
11. (14) De Rosa S, Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J 2014; 78: 567–575.
(14) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684–1692.
(14) Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, et al; on behalf of the Fushimi AF Registry Investigators. Inappropriate use of oral anticoagulants for patients with atrial fibrillation: 1-year outcomes of the Fushimi AF Registry. Circ J 2014; 78: 2166–2172.
(14) Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload: An interim result of post-marketing surveillance in Japan. Circ J 2014; 78: 844–852.
(14) Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495–502.
16. (13) Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: Primary results from the phase 2 YUKAWA study. Circ J 2014; 78: 1073–1082.
(13) Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H; for the J-RHYTHM Registry Investigators. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: An analysis of the J-RHYTHM Registry. Circ J 2014; 78: 1593–1599.
(13) Enomoto M, Ishizu T, Seo Y, Yamamoto M, Suzuki H, Shimano H, et al. Subendocardial systolic dysfunction in asymptomatic normotensive diabetic patients. Circ J 2015; 79: 1749–1755.
19. (12) Towbin JA. Inherited cardiomyopathies. Circ J 2014; 78: 2347–2356.
20. (11) Teshima Y, Takahashi N, Nishio S, Saito S, Kondo H, Fukui A, et al. Production of reactive oxygen species in the diabetic heart: Roles of mitochondria and NADPH oxidase. Circ J 2014; 78: 300–306.
(11) Campos CM, van Klaveren D, Iqbal J, Onuma Y, Zhang YJ, Garcia-Garcia HM, et al. Predictive performance of SYNTAX score II in patients with left main and multivessel coronary artery disease: Analysis of CREDO-Kyoto Registry. Circ J 2014; 78: 1942–1949.
(11) Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 2014; 78: 911–921.
(11) Kurisu S, Kihara Y. Clinical management of Takotsubo cardiomyopathy. Circ J 2014; 78: 1559–1566.
(11) Yoshihara T, Shimada K, Fukao K, Sai E, Sato-Okabayashi Y, Matsumori R, et al. Omega 3 polyunsaturated fatty acids suppress the development of aortic aneurysms through the inhibition of macrophage-mediated inflammation. Circ J 2015; 79: 1470–1478.
25. (10) Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases: Sarcoidosis, large-vessel arteritis, and atherosclerosis. Circ J 2014; 78: 1302–1310.
(10) Kubo T, Akasaka T, Kozuma K, Kimura K, Fusazaki T, Okura H, et al; on behalf of the NEXT Investigators. Vascular response to drug-eluting stent with biodegradable vs. durable polymer: Optical coherence tomography substudy of the NEXT. Circ J 2014; 78: 2408–2414.
(10) JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013): Digest version. Circ J 2014; 78: 2521–2562.
(10) Alfonso F, Bastante T, Rivero F, Cuesta J, Benedicto A, Saw J, et al. Spontaneous coronary artery dissection: From diagnosis to management. Circ J 2014; 78: 2099–2110.
(10) Gómez J, Reguero JR, Morís C, Martín M, Alvarez V, Alonso B, et al. Mutation analysis of the main hypertrophic cardiomyopathy genes using multiplex amplification and semiconductor next-generation sequencing. Circ J 2014; 78: 2963–2971.
(10) Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, et al; on behalf of the CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan: Report from the CHART studies. Circ J 2015; 79: 2396–2407.
(10) Okamura H, Kamakura T, Morita H, Tokioka K, Nakajima I, Wada M, et al. Risk stratification in patients with Brugada syndrome without previous cardiac arrest: Prognostic value of combined risk factors. Circ J 2015; 79: 310–317.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
